Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN EBITDA Margin
EBITDA as a percentage of revenue.
Legend Biotech CorporationNASDAQ: LEGN
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin widens to 17.9%
EBITDA Margin was 17.9% in Q3 FY2026, up 30.1 pp from a year earlier. On a trailing-twelve-month basis it was 7.3%, up 27.5 pp year over year. Over 3 fiscal years it widened by 333.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 15.4% for the fiscal year ending Dec 2026, up from -22.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 17.9%-0.0 pp QoQ
- Last fiscal yearDec 2025
- -22.6%-4.5 pp YoY
- LTMSep 2026
- 7.3%+27.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -22.6%
- Year-over-year change
- -4.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -22.6% | -4.5pp |
| FY2024 | 2024-12-31 | -18.0% | +149.5pp |
| FY2023 | 2023-12-31 | -167.6% | +188.4pp |
| FY2022 | 2022-12-31 | -356.0% | +214.1pp |
| FY2021 | 2021-12-31 | -570.1% | — |
EBITDA Margin vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 EBITDA Margin of 7.3% is the highest of the 10 companies compared; the peer median is -249.3%.
- Its year-over-year change of +27.5 pp is the 4th highest of 10, against a peer median of -20.8 pp.
- Over three fiscal years its change of +333.4 pp compares with a peer median of +126.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 7.3% | +27.5 pp | +333.4 pp | |
| FY2025 | 3.2% | +1695.0 pp | +2334.4 pp | |
| LTM Mar 2026 | -23.7% | -20.8 pp | +381.6 pp | |
| LTM Mar 2026 | -75.1% | -6.9 pp | +343.8 pp | |
| LTM Mar 2026 | -89.7% | -57.3 pp | +126.4 pp | |
| LTM Mar 2026 | -249.3% | +2401.7 pp | +1803.8 pp | |
| LTM Mar 2026 | -999.5% | +475.3 pp | -608.7 pp | |
| LTM Mar 2026 | -1859.1% | -709.8 pp | -1633.0 pp | |
| LTM Mar 2026 | -8932.3% | -8827.3 pp | -4917.5 pp | |
| LTM Mar 2026 | -770932.3% | -482924.6 pp | -730107.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding LEGN) | -249.3% | -20.8 pp | +126.4 pp | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| Weighted Avg Shares | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
| Weighted Avg Shares (Diluted) | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.